作者: 高歌 時(shí)間: 2025-3-22 00:18 作者: PURG 時(shí)間: 2025-3-22 03:18 作者: 加入 時(shí)間: 2025-3-22 07:21 作者: MAPLE 時(shí)間: 2025-3-22 11:16 作者: Dignant 時(shí)間: 2025-3-22 15:25
Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Ca safety profile on the other. Here, we briefly summarize the regulatory classification of immunotherapy approaches. The second part focuses on the evolving regulatory landscape for nonpersonalized and personalized cancer vaccines that have been in the focus of the CIMT regulatory research group during the last years.作者: Dignant 時(shí)間: 2025-3-22 17:13 作者: 表被動(dòng) 時(shí)間: 2025-3-22 21:35
The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic) conditions, engineered by viral vector- or nucleic acid-based gene transfer with the CAR, amplified to therapeutic numbers, and readministered to the patient. Successes in recent trials sustain the hope that specifically redirected patient T cells can control cancer in the long term.作者: 褻瀆 時(shí)間: 2025-3-23 03:37
Book 2014er Immunotherapy Meets Oncology. is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients..作者: HARD 時(shí)間: 2025-3-23 06:16
Book 2014nto an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identificat作者: 玉米棒子 時(shí)間: 2025-3-23 11:43
Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progressnvestigational methods. Together these improvements created the environment for reproducible and biology-driven clinical investigation of new compounds and thus a higher success rate. This chapter summarizes the methodological improvements for immunotherapy drug development and their application.作者: Acclaim 時(shí)間: 2025-3-23 16:03
Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation that are stable, functional, and easy to produce..It is obvious that for a successful translational process, the challenges mentioned above, scientific, nonscientific, or technical by nature, need to be met.作者: 不可救藥 時(shí)間: 2025-3-23 19:06 作者: TOXIC 時(shí)間: 2025-3-24 00:26 作者: photopsia 時(shí)間: 2025-3-24 06:08 作者: 破裂 時(shí)間: 2025-3-24 08:56
From Basic Immunology to New Therapies for Cancer Patientsincidence of cancer without an immune system constantly chasing and destroying newly developing cancer cells. “…Würden diese . nicht bestehen, so k?nnte man vermuten, dass das Karzinom in einer geradezu ungeheuerlichen Frequenz auftreten würde.” Independently of Paul Ehrlich, and earlier, two surgeo作者: Infantry 時(shí)間: 2025-3-24 13:56 作者: OVER 時(shí)間: 2025-3-24 17:35
Dendritic Cell-Based Cancer Vaccineser of patients. The results are even better if the DCs have been appropriately matured. However, only in a subset of patients, these encouraging results can be seen. Although the evidence on clinical responses is still limited, induced responses frequently result in long-term clinical effectiveness.作者: Arresting 時(shí)間: 2025-3-24 22:25
mRNA Vaccination and Personalized Cancer Therapycurrently utilized in the clinic by either transfecting antigen-presenting cells in vitro which are transferred back to the patient afterwards or by direct in vivo application to the patient. This chapter provides a short summary of the history of mRNA-based vaccination and introduces into the desig作者: TOXIN 時(shí)間: 2025-3-25 03:09
Antibody Therapy in Oncology. An attractive feature of this therapeutic strategy is the durable objective responses which are being seen in responding patients. The future for these and many other mAb-based drugs is very encouraging but will depend on the deep understanding of cancer biology, including its stroma and molecular作者: resilience 時(shí)間: 2025-3-25 03:44
The ABCs of T Cell Receptor Gene Therapytigens as target molecules for acute myeloid leukemia (AML) and applied several distinct approaches to acquire high-affinity TCRs for use in clinical studies. Each antigen and each TCR tells a different story and we have selected several examples to illustrate the hurdles in moving from bench to bed作者: 和平 時(shí)間: 2025-3-25 10:49 作者: 通便 時(shí)間: 2025-3-25 13:11 作者: 不規(guī)則的跳動(dòng) 時(shí)間: 2025-3-25 18:45 作者: 碎石頭 時(shí)間: 2025-3-25 21:23
ber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients..978-3-319-38126-8978-3-319-05104-8作者: 合唱團(tuán) 時(shí)間: 2025-3-26 00:42 作者: Counteract 時(shí)間: 2025-3-26 07:43
Dirk Buyens,Tine Vandenbossche,Ans De Vosguiding the choice and effect of therapy. In this chapter, the successes, new avenues, and challenges in immune monitoring of patients with cancer will be discussed in the context of current immunotherapeutic approaches.作者: 整潔漂亮 時(shí)間: 2025-3-26 08:45
Studies in Computational Intelligenceer of patients. The results are even better if the DCs have been appropriately matured. However, only in a subset of patients, these encouraging results can be seen. Although the evidence on clinical responses is still limited, induced responses frequently result in long-term clinical effectiveness.作者: 陰險(xiǎn) 時(shí)間: 2025-3-26 12:40 作者: OREX 時(shí)間: 2025-3-26 17:10 作者: 社團(tuán) 時(shí)間: 2025-3-27 00:15
New Challenges for Macroeconomic Policiestigens as target molecules for acute myeloid leukemia (AML) and applied several distinct approaches to acquire high-affinity TCRs for use in clinical studies. Each antigen and each TCR tells a different story and we have selected several examples to illustrate the hurdles in moving from bench to bed作者: Melatonin 時(shí)間: 2025-3-27 02:19 作者: 刻苦讀書(shū) 時(shí)間: 2025-3-27 08:13
https://doi.org/10.1007/978-3-031-62248-9 Safety and good immunogenicity of this novel approach were successfully demonstrated in a phase I/IIa study, and a further development of it is now in clinical phase IIb, proof-of-concept testing. These active immunotherapies can be combined successfully with other immunotherapies such as checkpoin作者: 使長(zhǎng)胖 時(shí)間: 2025-3-27 09:50
https://doi.org/10.1007/978-3-031-62478-0 interest in immunotherapeutic approaches for treatment of RCC. This chapter summarizes the recent developments in the treatment of RCC through immunotherapies approved or in clinical development as well as the immunological role of targeted therapies.作者: 疏忽 時(shí)間: 2025-3-27 15:52
How T Cells Single Out Tumor Cells: “And That Has Made All the Difference…”作者: 發(fā)酵劑 時(shí)間: 2025-3-27 20:35
From Basic Immunology to New Therapies for Cancer Patients agents and by the plasticity of the immune system to select such receptors and to make many copies on demand. Constructing “ein Gedankengeb?ude” to explain the observations made by Emil von Behring and Shibasaburo Kitasato (1890), he not only created the term “Antik?rper” (antibody) to describe suc作者: 免除責(zé)任 時(shí)間: 2025-3-28 00:40 作者: condone 時(shí)間: 2025-3-28 02:29
Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Cay products such as monoclonal antibodies have successfully been developed during the last years and contributed to major advances in cancer therapy. Development of cancer vaccines seemed to be more challenging. Nevertheless, some promising candidates are currently in late-stage clinical development,作者: Nucleate 時(shí)間: 2025-3-28 08:53 作者: 斜坡 時(shí)間: 2025-3-28 14:17
Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progressmmunotherapy extends beyond a century with its most noteworthy successes having occurred just in the last 3 years. New drugs in this space – both approved and under investigation – demonstrate increased levels of benefit for patients, and their development is based on progress in basic science and i作者: Notorious 時(shí)間: 2025-3-28 16:47
Reflections on Cancer Vaccinesn identified. These consist mainly of regulatory circuits in the cancer tissue that limits attack on tissues that are perceived as the body’s own tissue. Since cancer tissues masquerade as self-tissues, they eagerly employ these defense mechanisms such as PD-L1 expression on the tissue and induction作者: Hypomania 時(shí)間: 2025-3-28 19:24
Dendritic Cell-Based Cancer Vaccinescess antigen material and migrate to the lymphoid tissues where they present it on their surface in order to control the activation of the specific immunity. In particular the adaptive immune response, mediated by B and T cells, proved important in eradicating a tumour. This boosted the development 作者: HILAR 時(shí)間: 2025-3-29 01:10 作者: Mundane 時(shí)間: 2025-3-29 05:08 作者: ordain 時(shí)間: 2025-3-29 10:18
Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation engaged in the field since its early days struggling with its scientific as well as nonscientific challenges. This view is provided together with the perspective of a molecular biologist trying to solve the field’s most cumbersome technical problem, that is, the construction of bispecific molecules作者: COLON 時(shí)間: 2025-3-29 11:26
The ABCs of T Cell Receptor Gene Therapyerging clinical reality. Early patient studies of T cells engineered to express recombinant T cell receptors (TCRs) have revealed the potential of this potent form of immunotherapy, with better clinical success associated with use of higher-affinity TCRs. However, frequent, strong, or even lethal to作者: Ardent 時(shí)間: 2025-3-29 18:07
The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinicent of leukemia. The therapeutic approach utilizes patients’ T cells engineered ex vivo with a CAR which is a recombinant receptor molecule consisting in the extracellular part of an antibody-derived binding domain for major histocompatibility complex (MHC)-independent target recognition and in the 作者: 混亂生活 時(shí)間: 2025-3-29 21:36
Immunotherapy of Malignant Melanomathe field. Research performed in malignant melanoma has started to shape the field of cancer immunotherapy more than 20 years ago with the discovery of the first tumor-associated antigens documented to be recognized by antigen-specific T cells in patients. As discussed in the following sections, the作者: Celiac-Plexus 時(shí)間: 2025-3-30 02:50
Prostate Cancer Vaccines Generated with the Disruptive RNActive? Technology Follow the Path Paved bye carcinoma rather than in melanoma, the test disease for many immunotherapies in the past. Sipuleucel-T is followed suit by other vaccines against prostate carcinoma that are now on advanced clinical development paths. Prostvac-VF is a viral vector vaccine using a heterologous prime–boost regimen t作者: 減至最低 時(shí)間: 2025-3-30 06:08 作者: mighty 時(shí)間: 2025-3-30 08:29
https://doi.org/10.1057/9780230597952 agents and by the plasticity of the immune system to select such receptors and to make many copies on demand. Constructing “ein Gedankengeb?ude” to explain the observations made by Emil von Behring and Shibasaburo Kitasato (1890), he not only created the term “Antik?rper” (antibody) to describe suc作者: 流浪者 時(shí)間: 2025-3-30 14:00 作者: guardianship 時(shí)間: 2025-3-30 18:43
Dirk Buyens,Tine Vandenbossche,Ans De Vosy products such as monoclonal antibodies have successfully been developed during the last years and contributed to major advances in cancer therapy. Development of cancer vaccines seemed to be more challenging. Nevertheless, some promising candidates are currently in late-stage clinical development,作者: 高歌 時(shí)間: 2025-3-30 23:19
Dirk Buyens,Tine Vandenbossche,Ans De Vosng T cells and studies consequently showing that therapeutic interventions which are based on transfer, activation and expansion, or de-blocking of tumor-specific T cells, which have met with clinical success. To optimally profit from the flow of newly developed immune-based therapeutics aiming to r作者: Increment 時(shí)間: 2025-3-31 02:42
Dirk Buyens,Tine Vandenbossche,Ans De Vosmmunotherapy extends beyond a century with its most noteworthy successes having occurred just in the last 3 years. New drugs in this space – both approved and under investigation – demonstrate increased levels of benefit for patients, and their development is based on progress in basic science and i作者: 情感 時(shí)間: 2025-3-31 07:48 作者: admission 時(shí)間: 2025-3-31 09:17 作者: 助記 時(shí)間: 2025-3-31 14:07
New Challenges for Macroeconomic Policiesnherent adjuvant activity. As compared to DNA-based approaches, in vitro-transcribed messenger RNA (mRNA) is a safer drug format due to the adjustable, transient expression and lack of genomic integration. In contrast to viral vector vaccines, mRNA vaccination is not limited by the emergence of immu
